James C. Foster, an insider at Charles River Laboratories International, Inc. (CRL), sold 24,042 shares on 2026-10-22 at $350.00 per share, a transaction worth about $8.41 million. The size of the sale makes it notable, but it was executed under a pre-scheduled Rule 10b5-1 trading plan, meaning the sale was set up in advance and carried out automatically under predefined conditions. Foster’s role matters because trades by senior leaders and long-tenured insiders can draw attention as a window into how management manages personal exposure to the stock. A 10b5-1 plan can reduce the informational value of a trade because it is designed to limit discretionary timing, which is why this type of sale is often viewed as more routine than an open-market, ad hoc decision. Looking at recent activity, CRL has seen two insider sales over the past 30 days: Foster’s $8.41 million sale and a smaller sale by Shannon M. Parisotto for about $742,550 on 2026-10-21. With only sales reported in the recent period and no insider buys listed, the pattern points to insiders trimming holdings rather than adding, though the presence of a 10b5-1 plan suggests at least part of this activity may reflect planned liquidity or diversification rather than a change in company outlook.